Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Barinthus Biotherapeutics plc.

Get SEC filing alerts via email and in your feed for Barinthus Biotherapeutics plc.

BRNS

Barinthus Biotherapeutics plc.

About Barinthus Biotherapeutics plc.

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory diseases, infectious diseases, and cancer. Its proprietary SNAP-TI platform promotes immune tolerance by modulating T cell responses, while viral vector platforms (ChAdOx and MVA) induce robust CD8+ T cell immunity. The company’s pipeline includes candidates for celiac disease, chronic hepatitis B, HPV, and various cancers, leveraging advanced antigen design and delivery technologies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Barinthus Biotherapeutics plc.

1
1
Barinthus Biotherapeutics plc. Barinthus Biotherapeutics Reports $5.5 Million Net Loss in Q1 2026, Sees Significant Expense Reductions

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Barinthus Biotherapeutics plc. Barinthus Biotherapeutics Reports $66.5 Million Net Loss and Strategic Shift Towards Immunology

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Barinthus Biotherapeutics plc. Barinthus Biotherapeutics Reports No Revenue and $14.57M Net Loss in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Barinthus Biotherapeutics plc. Barinthus Biotherapeutics Reports $21.1 Million Net Loss for Q2 2025, Focuses on Immunology Programs

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Barinthus Biotherapeutics plc. Barinthus Biotherapeutics Reports $19.7 Million Net Loss and Focus on Immunotherapy Pipeline

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Barinthus Biotherapeutics plc. Barinthus Biotherapeutics Reports $61.2M Net Loss and $15M Revenue for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Barinthus Biotherapeutics plc. Barinthus Biotherapeutics Reports Mixed Financial Results, Shifts Focus to Key Product Candidates

Via official filing (AI summary) | over 1 year ago | 0 comments